US drug pricing pressure impacts pharmaceutical market access in Switzerland

Interpharma reports that US-driven global pricing pressures are causing pharmaceutical companies to delay or withhold the launch of new medications in Switzerland. It remains unclear if this is a strategic negotiation tactic or a structural shift in market prioritization by manufacturers.